AstraZeneca to Invest $2.5 Billion in China Amid Probes
The drugmaker plans to build a research-and-development center in Beijing and strike deals with local biotechnology companies ...
AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals
AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...
AstraZeneca to build $2.5B research hub in Beijing
AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational ...
J&J Passes AstraZeneca in Lung Cancer Drug Race — For Now
Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer ...
Fierce Pharma9h
J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca's Tagrisso
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...
China Daily2d
AstraZeneca puts faith in innovation
Multinational pharmaceutical company AstraZeneca is bullish about China's role as a global innovation powerhouse, underpinned ...
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a ...
Fierce Pharma1d
AstraZeneca, Pfizer rebuked over breaking UK drug marketing rules on LinkedIn use
The PMCPA has dug into the industry’s LinkedIn activities once again. | The PMCPA has dug into the industry’s LinkedIn ...
After China probe, is AstraZeneca’s new US$2.5 billion plan a blueprint for foreign firms?
British-Swedish drug maker has gone from Beijing’s scrutiny to its praise, hailed as a sign of doing business in China.
AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy
Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...